Emerging studies have illuminated that NLGN3 acts on glioma cells accompanied by activation of the extracellular regulated protein kinases (ERK) pathway and nuclear factor kappa‐B (NF‐κB) pathway [45, 136]. Here, NLGN3 is linked to central nervous system cancer.